DB-1303 vs. SOC in HER2low, HER+ Metastatic breast cancer

A Phase 3, Randomized, Multi-center, Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy

Disease Types: Breast

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Phase 3, Randomized, Multi-center, Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy

For More Information:

https://clinicaltrials.gov/study/NCT06018337?term=A%20Phase%203,%20Randomized,%20Multi-center,%20Open-label%20Study%20of%20DB-1303%20Versus%20Investigator%27s%20Choice%20Chemotherapy%20in%20Human%20Epidermal%20Growth%20Factor%20Receptor%202%20(HER2)-low,%20Hormone%20Receptor%20Positive%20(HR%2B)%20Metastatic%20Breast%20Cancer%20Patients%20whose%20Disease%20has%20Progressed%20on%20Endocrine%20Therapy&rank=1